Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CORT | CLUSTER | neutral | 3/10 | CEO Joseph Belanoff sold $895K worth of CORT shares on June 1, and two other executives sold a combined $3.9M on May 27, | Jun 3, 2026 |
| EXEL | CLUSTER | neutral | 2/10 | Two Exelixis directors sold a total of ~$690K in open-market transactions over a 7-day window, representing ~0.006% of t | Jun 3, 2026 |
| LODE | CLUSTER | bullish | 5/10 | Two insiders at Comstock Inc. made open-market purchases totaling $71K in early June 2026, including CEO Corrado DeGaspe | Jun 3, 2026 |
| OTLK | CLUSTER | bullish | 7/10 | A significant insider buying cluster at Outlook Therapeutics, totaling $5.25M in open-market purchases, is dominated by | Jun 3, 2026 |
| ALEC | CLUSTER | neutral | 3/10 | CEO Arnon Rosenthal and CFO Neil Berkley sold a combined $210K in open-market sales on June 2, 2026, with the CEO alone | Jun 3, 2026 |
| TRIB | F-1/A | bearish | 6/10 | Trinity Biotech filed Post-Effective Amendment No. 1 to its F-1 registration statement, updating the prospectus to inclu | Jun 3, 2026 |
| CELUW | 8-K | neutral | 3/10 | Celularity appointed Rick Gonzalez as Chief Commercial Officer (effective May 29, 2026) and issued a shareholder letter | Jun 3, 2026 |
| GWTI | 8-K | neutral | 3/10 | Raymond Wright resigned as Chairman of the Board and Interim President of Greenway Technologies, effective May 28, 2026. | Jun 3, 2026 |
| ANAB | 144 | bearish | 5/10 | CEO Dennis Mulroy filed a Form 144 to sell 20,000 shares (~$1.0M at filing) via a stock option exercise, signaling inten | Jun 3, 2026 |
| LIMNW | 8-K | mixed | 5/10 | Liminatus Pharma entered into a warrant inducement agreement whereby an accredited investor exercised approximately 10.3 | Jun 3, 2026 |
| JAZZ | CLUSTER | neutral | 3/10 | Three Jazz Pharmaceuticals insiders sold a total of $3.32M in open-market transactions over a 7-day window, including th | Jun 3, 2026 |
| SILO | 8-K | neutral | 4/10 | Silo Pharma filed a Certificate of Change effecting a 1-for-15 reverse stock split, effective June 2, 2026, to regain co | Jun 3, 2026 |
| MAZE | CLUSTER | bearish | 4/10 | Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, including the CEO, Pre | Jun 3, 2026 |
| IQV | 8-K | neutral | 3/10 | IQVIA announced that its wholly owned subsidiary intends to raise €950 million through an offering of senior notes due 2 | Jun 3, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and CFO James Edgemond sold a combined ~$1.41M in UTHR shares over five trading days, entirely fro | Jun 3, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Three Liquidia Corp insiders sold a total of ~$1.32M in open-market transactions over a one-week window ending June 1, 2 | Jun 3, 2026 |
| ADCT | 8-K | mixed | 6/10 | ADC Therapeutics announced topline results from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA (loncastuximab tesiri | Jun 3, 2026 |
| NRXPW | 424B5 | bearish | 6/10 | NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286 shares of common stock at | Jun 3, 2026 |
| JBIO | 424B5 | bearish | 6/10 | Jade Biosciences filed a preliminary 424B5 prospectus supplement for an underwritten public offering of common stock and | Jun 3, 2026 |
| VRTX | CLUSTER | neutral | 2/10 | Two senior executives at Vertex Pharmaceuticals (EVP/CMO and EVP/Chief Legal Officer) sold a combined $1.25M in open-mar | Jun 3, 2026 |
| XENE | 8-K | neutral | 3/10 | Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where shareholders approved | Jun 3, 2026 |
| JBIO | PRESS-RELEASE | bearish | 6/10 | Jade Biosciences announced an underwritten public offering of common stock and pre-funded warrants, with a 30-day underw | Jun 3, 2026 |
| QURE | 144 | neutral | 2/10 | Director Jack Kaye filed a Form 144 notice of intent to sell 2,645 ordinary shares of uniQure N.V., valued at approximat | Jun 3, 2026 |
| NOTV | 8-K | bearish | 8/10 | Inotiv files for Chapter 11 bankruptcy with a prepackaged plan that cancels all existing common equity. Total funded deb | Jun 3, 2026 |
| NYMXF | 6-K | bearish | 6/10 | Nymox Pharmaceutical provided an update on its drug Nymozarfex (TM) for BPH. The initial US submission was not accepted | Jun 3, 2026 |
| MAIA | PRESS-RELEASE | bullish | 6/10 | MAIA Biotechnology announced FDA clearance of an IND amendment to open U.S. enrollment for the expansion of its Phase 2 | Jun 3, 2026 |
| IVEVF | 6-K | neutral | 2/10 | Inventiva S.A. filed a 6-K announcing the mailing of proxy cards for its Ordinary and Extraordinary General Meeting sche | Jun 3, 2026 |
| HROW | 8-K | neutral | 3/10 | Harrow, Inc. filed an 8-K under Item 7.01 to furnish a June 2026 corporate presentation for use at investor conferences. | Jun 3, 2026 |
| AXSM | 8-K | bullish | 7/10 | Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier than March 2040 (or | Jun 3, 2026 |
| REX | 8-K | neutral | 3/10 | REX American Resources held its 2026 Annual Meeting on May 28, 2026, where shareholders approved the 2026 Incentive Plan | Jun 3, 2026 |